For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Improvements in influenza immunisation coverage in 2020, but equity gaps remain
+Practice
In print
VACCINES
Improvements in influenza immunisation coverage in 2020, but equity gaps remain
Wednesday 19 August 2020, 01:00 AM
Figure 1. 2020 NIR influenza immunisation coverage in the 65+ age group, by ethnicity. Figure 2. 2020 NIR influenza immunisation coverage for Māori, Pacific and the overall population, by age group (as at 26 June 2020)
This article reports on the successes of the Influenza Immunisation Programme under the exceptional circumstances of COVID-19
Barbara McArdle
2020 Pharmac eligibility clarification, Asthma is one health condition that impacts eligibility for a funded influenza vaccination. The New Zealand Pharmaceutical Schedule states eligibility, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.